Volume 6 Supplement 2
Edited by Peter E Lipsky and Ravinder N Maini
Supported by an educational grant from Centocor, Inc.
Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved the outcomes in patients with rheumatoid arthritis (RA). At this report, safety data were collected on a...
The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are a...
Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved functional outcomes in patients with rheumatoid arthritis (RA). RA is a progressive disease in which str...
Ankylosing spondylitis (AS) is a member of the family of spondyloarthropathies, which are inflammatory arthritides largely involving the axial skeleton and commonly accompanied by peripheral arthritis. Genetic...
Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA – infliximab, etanercept, and adalimumab – have been de...
Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy that commonly appears after the onset of the characteristic cutaneous lesions. This complication affects about 40% of patients with moderate to s...
2022 Citation Impact
4.9 - 2-year Impact Factor
5.7 - 5-year Impact Factor
1.501 - SNIP (Source Normalized Impact per Paper)
1.592 - SJR (SCImago Journal Rank)
2023 Speed
11 days submission to first editorial decision for all manuscripts (Median)
111 days submission to accept (Median)
2023 Usage
3,331,819 downloads
1,885 Altmetric mentions